Desentum, a clinical-stage biotechnology company developing novel allergen immunotherapies, announced today that the first trial participants have received their first doses in a Phase 2 clinical study, BASIT, evaluating DM-101PX for treatment of birch pollen allergy. The study is being conducted in Canada, following regulatory approval earlier this year.
DM-101PX is an investigational immunotherapy intended to provide long-lasting relief from allergy symptoms triggered by birch pollen, with a shorter treatment regimen compared to traditional allergen immunotherapy. The BASIT study is a randomised, double-blind, placebo-controlled Phase 2 study designed to demonstrate the clinical effect of a short-course treatment on allergic symptoms induced by a nasal allergen challenge and to evaluate the persistence of this effect.
“This milestone is not only important for birch pollen allergy sufferers but also for Desentum’s broader mission,” said Pekka Mattila, CEO of Desentum. “The BASIT study is a key step in validating our platform technology, which we believe can be applied to develop faster and more effective treatments for a wide range of allergies.”
The study will be completed in Q3/2026, with topline results expected in late 2026.
About DM-101PX
The active substance in DM-101PX is DM-101, a recombinant birch pollen allergen modified to reduce its allergenic potential. DM-101PX contains a formulation optimized to support the controlled release of DM-101 after subcutaneous injection.
About Desentum
Desentum Oy is a clinical-stage biopharmaceutical company based in Espoo, Finland, leveraging high-resolution protein engineering and novel formulations for designing allergy vaccines that enable short-course treatment to restore long-term tolerance. Desentum, founded in 2011, is a spin-off company from VTT Technical Research Centre of Finland Ltd. With its product development, Desentum targets both respiratory and food allergies.